149 related articles for article (PubMed ID: 38207224)
21. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
Starenki D; Hong SK; Wu PK; Park JI
Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
[TBL] [Abstract][Full Text] [Related]
22. Disseminated medullary thyroid cancer - an alternative therapeutic approach.
Wilczyńska M; Suchmiel M; Sokołowski G; Hubalewska-Dydejczyk A; Trofimiuk-Müldner M
Endokrynol Pol; 2022; 73(5):909-910. PubMed ID: 35971935
[TBL] [Abstract][Full Text] [Related]
23. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
[TBL] [Abstract][Full Text] [Related]
25. Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
Pitoia F; Bueno F; Schmidt A; Lucas S; Cross G
Arch Endocrinol Metab; 2015 Aug; 59(4):343-6. PubMed ID: 26331322
[TBL] [Abstract][Full Text] [Related]
26. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
27. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Valerio L; Bottici V; Matrone A; Piaggi P; Viola D; Cappagli V; Agate L; Molinaro E; Ciampi R; Tacito A; Ramone T; Romei C; Elisei R
Endocr Relat Cancer; 2020 Jan; 27(2):97-110. PubMed ID: 31804969
[TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
Maciel LMZ; Magalhães PKR
Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
[TBL] [Abstract][Full Text] [Related]
29. Vandetanib (Caprelsa) for medullary thyroid cancer.
Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
[No Abstract] [Full Text] [Related]
30. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Kreissl MC; Bastholt L; Elisei R; Haddad R; Hauch O; Jarząb B; Robinson B; Colzani R; Foster M; Weiss R; Schlumberger M
J Clin Oncol; 2020 Aug; 38(24):2773-2781. PubMed ID: 32584630
[TBL] [Abstract][Full Text] [Related]
32. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Hadoux J; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
[TBL] [Abstract][Full Text] [Related]
34. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
35. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM
Thyroid; 2014 Jan; 24(1):43-51. PubMed ID: 24256343
[TBL] [Abstract][Full Text] [Related]
36. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
Ton GN; Banaszynski ME; Kolesar JM
Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
[TBL] [Abstract][Full Text] [Related]
37. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
38. An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.
García-Moreno RM; Moreno-Domínguez Ó; Castelo-Fernández B; Yébenes-Gregorio L; Torres-Sánchez I; Álvarez-Escolá C
Oncol Res Treat; 2021; 44(10):568-572. PubMed ID: 34515201
[TBL] [Abstract][Full Text] [Related]
39. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
40. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
